
Weight-loss jabs sharpen a class divide among middle-aged women
New Health Foundation data shows middle-class women aged 30–50 are the dominant private-prescription users of weight‑loss injections like Ozempic and Mounjaro, prompting debate over affordability, ethics, and long-term health effects as researchers highlight side effects and a growing class divide in obesity treatment.













